19,972 Shares in Edwards Lifesciences Corporation $EW Purchased by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 19,972 shares of the medical research company’s stock, valued at approximately $1,807,000.

Several other hedge funds have also recently modified their holdings of EW. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences in the 1st quarter valued at $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, TrinityBridge Ltd bought a new position in Edwards Lifesciences during the second quarter valued at about $27,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on EW shares. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Mizuho raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Truist Financial lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. UBS Group began coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. Finally, Evercore reiterated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Up 0.3%

Edwards Lifesciences stock opened at $90.19 on Friday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The firm has a market capitalization of $51.93 billion, a price-to-earnings ratio of 51.83, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $89.54 and a 200 day simple moving average of $85.03.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 earnings per share. The business’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Annette Bruls sold 2,644 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 4,501 shares of company stock worth $408,213. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.